logo-loader
HealthMedical technology & services
VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics bolsters expansion plans with new business advisory committee

Samuel Schwartz has been named as the BAC's inaugural chairman

doctor with patient
The firm's heart monitoring system allows clinicians to assess heart function

VentriPoint Diagnostics Ltd (CVE:VPT) has further bolstered its expansion plans, establishing a business advisory committee (BAC) and naming Samuel Schwartz as its inaugural chairman.

"We are very pleased to have Sam's many years of assisting small companies to grow internationally at our disposal," said Dr George Adams, chief executive at medtech firm Ventripoint.

"This is especially important at this time as the company looks at strategic approaches to growing its business."

"I am excited to have the opportunity to bring together a world-class group to advise Ventripoint on its goal to achieve better cardiac diagnosis and monitoring for everyone, especially children," said Dr Schwartz.

Schwartz was the managing partner of the Toronto office of DLA Piper Canada LLP, where he practised in many areas of the law, including corporate finance, structuring and securities law, and merchant banking.

His diverse clients included Canadian and foreign companies involved in the life sciences, biotech, computer hardware and software markets.

Last month, Ventripoint revealed it was among the top 50 performers on the TSX venture exchange over the last year, according to the exchange's ranking system.

The group has pioneered the VMSplus heart analysis device, and it (the company) has been added to the 2018 TSX Venture 50.

"2017 was a historical year for Ventripoint, our employees and shareholders, who have seen the company increase in market capitalisation by 384% and experience share price appreciation of 258%, while trading 206 million shares on the TSX Venture Exchange and 250mln shares on all share exchanges," said Dr Adams.

Its VMS Plus is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound.

The company has developed a suite of applications for all major heart diseases and is actively commercialising the approach to improve cardiac care.

Quick facts: VentriPoint Diagnostics Ltd.

Price: $0.11

Market: TSX-V
Market Cap: $6.8 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Qrons seeking to find a cure for traumatic brain injuries...

Qrons Inc (OTCQB: QRON) CEO Jonah Meer tells Proactive the New York-based biotechnology company is developing two products, one of which involves a 3D-printable scaffold, aimed at helping to treat traumatic brain injuries. Meer says that traumatic brain injuries are the number one cause of...

7 hours, 12 minutes ago

2 min read